Nisa Investment Advisors LLC Has $63,000 Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Nisa Investment Advisors LLC trimmed its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 31.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,154 shares of the biotechnology company’s stock after selling 1,453 shares during the period. Nisa Investment Advisors LLC’s holdings in ADMA Biologics were worth $63,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its stake in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after buying an additional 92,281 shares during the last quarter. LSV Asset Management acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $1,028,000. Seven Eight Capital LP acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,992,000. Louisiana State Employees Retirement System acquired a new position in shares of ADMA Biologics during the 3rd quarter worth about $2,253,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of ADMA Biologics by 152.2% during the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock worth $4,837,000 after buying an additional 442,315 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 over the last three months. Insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ADMA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a research note on Monday, October 14th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Trading Up 0.3 %

Shares of NASDAQ:ADMA opened at $19.72 on Friday. ADMA Biologics, Inc. has a 52-week low of $3.56 and a 52-week high of $21.13. The company has a market capitalization of $4.60 billion, a P/E ratio of 140.86 and a beta of 0.64. The company has a 50-day simple moving average of $18.01 and a 200 day simple moving average of $13.73. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period last year, the business posted ($0.02) earnings per share. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.